Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (4033)	12/12/2015 11:03:21 AM
From: tktom	Respond to of 4474

jaybe, good point. For the first time in Harvey's career, he may have stated a date for approval of '113 further out (Early 2017)) than actual. Actually, I wished they would not go forward with Optic 2L trial for Ponatinib, but rather accelerate a head to head first line trial with Criz. I expect the Ponatinib name is forever tarnished, no matter what the second line results.

To: jaybe who wrote (4033)	12/12/2015 11:15:56 AM
From: kenyonn	Read Replies (3) \| Respond to of 4474

They need to file an NDA before the FDA will consider approving the drug, priority review or otherwise. Ariad has stated they intend to file in the 3rd quarter of 2016. Unless they're lying to us, I don't see approval happening before end of 2016/early 2017. Frankly, I find the delay in reporting early results from the ALTA trial concerning. I suppose it could simply be that they didn't get enough patients enrolled and mature data points in time to be ready for ASH. But pushing them all the way to ASCO 2016 doesn't make much sense to me. There's been speculation that this is because they are privately showcasing those early results to suitors, but that makes little sense either. If they're good, why not go public? It won't matter one way or another to negotiations--in fact, with the rise in share price that would undoubtably occur, it could strengthen price negotiations. Has anyone heard any rumblings of continued issues with the pulmonary side effects of the drug? At least publicly, Ariad has been pretty adamant that they have them under control. But I'm not inclined to believe everything they say. I don't want to end up in another situation where the FDA disagrees with Ariad's assessment of risk, and us small investors are caught in the crossfire.